NCT03423186View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

October 25, 2019

Study Completion Date

October 25, 2019

Conditions
Sanfilippo Syndrome Type A (MPS IIIA)
Interventions
DRUG

SOBI003

Weekly i.v.infusion

Trial Locations (4)

27599

University of North Carolina Hospitals, Chapel Hill

94609

Childrens's Hospital and Research Center, Oakland

Unknown

University Medical Center Hamburg-Eppendorf, Hamburg

Gazi University Hospital, Ankara

Sponsors
All Listed Sponsors
lead

Swedish Orphan Biovitrum

INDUSTRY

NCT03423186 - A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients | Biotech Hunter | Biotech Hunter